Decapeptide-12 cosmetic peptide suspension · peptide found in Lumixyl-class actives™ / P4 · tyrosinase-inhibitor decapeptide · choose base, strength, and preservation
Decapeptide-12, a potent peptide found in Lumixyl-class actives, offers targeted brightening without cytotoxicity; Formulate Labs supplies Decapeptide-12 only and does not sell Lumixyl.
P4 sequence · Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr · CAS 147732-56-7
Decapeptide-12 operates as a targeted, competitive inhibitor of the tyrosinase enzyme, effectively blocking the oxidation of L-tyrosine to L-DOPA – a crucial step in melanin synthesis – without the cytotoxic effects associated with traditional agents like hydroquinone. Beyond pigmentation control, Decapeptide-12 demonstrates anti-senescence properties by upregulating sirtuin transcription (SIRT1, SIRT3, SIRT6) in epidermal keratinocytes. This dual mechanism positions Decapeptide-12 as a premium, non-irritating brightening active ideal for addressing melasma, age spots, and post-inflammatory hyperpigmentation across diverse skin profiles.
Market context: — Decapeptide-12 gained recognition in supplier-branded systems like Lumixyl, frequently positioned as a non-toxic clinical alternative to traditional hydroquinone-based treatments for recalcitrant melasma. These systems often pair Decapeptide-12 with synergistic epidermal-turnover actives, such as buffered glycolic acid and antioxidant cleansers, to maximize visible brightening efficacy. Formulate Labs provides the pure INCI ingredient, Decapeptide-12, exclusively, empowering brands to craft proprietary formulations and differentiate their products without being confined to specific supplier-branded SKUs.
Formulate Labs supplies Decapeptide-12 in stable, easy-to-handle suspensions, utilizing high-quality cosmetic carriers such as Glycerin/Water or Sea Kelp Bioferment. These pre-dispersed concentrates are typically available at 0.1% or 1% active peptide strengths, offering formulators excellent downstream flexibility. This allows for precise integration into diverse cosmetic bases, achieving optimal active use levels ranging from 0.01% to 0.1% for effective and consistent results.
Hair & scalp note: because its core mechanism suppresses melanin synthesis, this is not a hair-growth or hair-shaft peptide. If used near the scalp, restrict to oily, inflamed, or acne-prone scalp serums only — and avoid delivery paths that could reach follicular melanocytes (theoretical depigmentation / premature graying risk). For growth-positioned hair care, formulators typically choose Copper Tripeptide-1, Biotinoyl Tripeptide-1, Decapeptide-10, or Decapeptide-18 instead.*
These attributes are assessments based on the ingredient deck and the supplier information available to us. They are not third-party certifications (no Kosher, Halal, Vegan, or similar certifying body has audited or issued a certificate for this material). If your finished product requires a specific certified status, please reach out and we’ll walk through what we can document.
Every lot is produced to order in our AI-powered robotic factory. Nothing sits on a warehouse shelf going stale - you get a date-of-manufacture-fresh batch every time.
Decapeptide-12 is the INCI name for this peptide; trade names like Lumixyl refer to specific supplier-branded active systems, which Formulate Labs does not sell.
Decapeptide-12 (Lumixyl / P4) is documented in dermatology and cosmetic-science literature as a reversible tyrosinase inhibitor for melasma, solar damage, and post-inflammatory hyperpigmentation — with published brightening-system clinical work at 0.01% peptide loading. These are independent, third-party papers we link for formulators evaluating mechanism, tolerability, and published panel data. We did not conduct this research and do not guarantee replication in your finished formula.
16-week open-label study in Hispanic females reporting tolerable use and progressive MASI score reductions with a Lumixyl-style 0.01% decapeptide-12 brightening regimen plus buffered glycolic acid and SPF.
Case-series evaluation of a four-step Lumixyl brightening system reporting melasma improvement, including complete clearance in one of four patients at six weeks.
Open-label brightening-system study reporting cosmetic improvement in hyperpigmentation appearance with decapeptide-12–containing regimens.
Reports accelerated cosmetic resolution of post-inflammatory hyperpigmentation with decapeptide-12 delivery approaches relevant to PIH-positioned skincare.
These citations are provided for informational and formulation-research purposes only. Study designs, concentrations, vehicle systems, and populations vary and may not match the suspensions on this page. Published results do not constitute FDA or EU cosmetic claim substantiation for your brand. Always review the primary literature and consult your regulatory counsel before making structure/function statements on finished products.
This is the per-ingredient composition of the suspension as it ships. Updates dynamically when you change the base, strength, or preservation system above. The peptide line shows the DP-12 loading; the preservative line shows the supplier-blend percentage with its sub-ingredients nested below.
SDS + TDS are issued per recipe (each base / preservative combination has its own regulatory paperwork). The links below swap when you change your selection above. COA is batch-specific and ships with the order.
